

MosaMedix joins European SKiN-HUID consortium for development of novel platform for Targeted Cancer Therapy.

November 2016

MosaMedix BV is very pleased to have joined a Consortium of Academic Centres and commercial Companies in Belgium and The Netherlands in the SKiN-HUID project. The Consortium is supported financially by the Interreg V program of Interreg Flanders-Netherlands and EFRO (Europees Fonds voor Regionale Ontwikkeling). The Dutch Partners also enjoy sponsoring from the Province of Limburg (NL) and the Dutch Ministry of Economic Affairs.

The objective of the collaboration is to create novel targeted treatments of cancer by integrating innovative technologies.

MosaMedix contributes with its Annexin-technology platform to the design of tumour targeting compounds. The consortium will employ skin-tumour models (melanoma) for validation of the technology.

The VIB-Lab of Dr. Chris Marine at KU-Leuven provides world-class expertise on skin cancer and especially melanoma cancer for this project. The Laboratory of Professor John-Paul Bogers at the University of Antwerp is key to excellent biomedical microscopy and analysis and toxicology of animal models. With the Laboratory of Professor Reutelingsperger at Maastricht University the project has access to unique expertise and biochemical technology on annexins and coupling techniques. Basic Pharma Group will contribute expertise and facilities for development of GMP manufacturing and pharmaceutical formulations in collaboration with MosaMedix.

